@article{d160c45037234d4990923be7d8ad9105,
title = "Sleep apnea and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA): leveraging state-of-the-art vascular imaging",
abstract = "Purpose: To further characterize the relationship between obstructive sleep apnea (OSA) and carotid atherosclerosis, we examined the structural and metabolic features of carotid plaque using hybrid 18-F-fluorodeoxyglucose (FDG) Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) in the Multi-Ethnic Study of Atherosclerosis (MESA). Methods: We studied 46 individuals from the MESA-PET and MESA-Sleep ancillary studies. OSA was defined as an apnea hypopnea index [AHI] ≥ 15 events per hour (4% desaturation). PET/MRI was used to measure carotid plaque inflammation (using target-to-background-ratios [TBR]) and carotid wall thickness (CWT). Linear regression was used to assess the associations between OSA, CWT and TBR. Results: The mean age was 67.9 years (SD 8.53) and the mean BMI was 28.9 kg/m2 (SD 4.47). There was a trend toward a higher mean CWT in the OSA (n = 11) vs. non-OSA group (n = 35), 1.51 vs. 1.41 (p = 0.098). TBR did not differ by OSA groups, and there was no significant association between OSA and carotid plaque inflammation (TBR) in adjusted analyses. Although there was a significant interaction between OSA and obesity, there were no statistically significant associations between OSA and vascular inflammation in stratified analysis by obesity. Conclusion: Despite a trend toward a higher carotid wall thickness in OSA vs. non-OSA participants, we did not find an independent association between OSA and carotid plaque inflammation using PET/MRI in MESA. Our findings suggest that simultaneous assessments of structural and metabolic features of atherosclerosis may fill current knowledge gaps pertaining to the influence of OSA on atherosclerosis prevalence and progression.",
keywords = "Atherosclerosis, Carotid wall thickness, MESA, OSA, Obesity, Obstructive sleep apnea, PET/MRI, Vascular inflammation",
author = "Neomi Shah and Michelle Reid and Venkatesh Mani and Vaishnavi Kundel and Kaplan, {Robert C.} and Kizer, {Jorge R.} and Fayad, {Zahi A.} and Steven Shea and Susan Redline",
note = "Funding Information: This research was supported by contracts with University of Washington Coordinating Center (HHSN268201500003I, N01-HC-95159), UCLA Field Center (N01-HC-95160), Columbia University Field Center ( N01-HC-95161), Johns Hopkins University Field Center (N01-HC-95162), University of Minnesota Field Center (N01-HC-95163), Northwestern University Field Center (N01-HC-95164), Wake Forest University Field Center (N01-HC-95165),Central Laboratory (N01-HC-95166), Ultrasound Reading Center (N01-HC-95167), MRI Reading Center (N01-HC-95168) and CT Reading Center (N01-HC-95169) from the National Heart, Lung, and Blood Institute, and by grants UL1-TR-000040 (Columbia CTSA), UL1-TR-001079 (Johns Hopkins ICTR), and UL1-TR-001420 (Wake Forest University CTSA) from NCATS. The MESA Sleep study was support by NHLBI grant R01HL56984. The MESA-PET study was supported by NHLBI grant R01HL127637. Dr. Susan Redline was partially supported by R35 HL135818. Dr. Neomi A Shah has funding from the National Institute of Health/National Heart, Lung, and Blood Institute (1R03HL140273-01, 1R01HL143221-01). Funding Information: Ms. Michelle Reid declares that she has no conflict of interest. Dr. Venkatesh Mani declares that he has no conflict of interest. Dr. Vaishnavi Kundel declares that she has no conflict of interest. Dr. Robert Kaplan declares that he has no conflict of interest. Dr. Zahi Fayad declares that he has no conflict of interest. Dr. Steven Shea declares that he has no conflict of interest. Dr. Neomi Shah reports receiving funding and consulting funds from Itamar and Respicardia, unrelated to this project and stock ownership in Abbott Laboratories. Dr. Susan Redline reports receiving grants and consulting funds from Jazz Pharmaceuticals and consulting fees from Eisai Pharmaceuticals, unrelated to this project. Dr. Jorge Kizer reports stock ownership in Abbott, Bristol-Myers Squibb, Johnson & Johnson, Medtronic, Merck and Pfizer. Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Nature B.V.",
year = "2023",
month = mar,
doi = "10.1007/s10554-022-02743-4",
language = "English",
volume = "39",
pages = "621--630",
journal = "International Journal of Cardiovascular Imaging",
issn = "1569-5794",
number = "3",
}